DE69625696T2 - Verwendung eines thienotriazoldiazepins zur erhöhung des apolopoproteins a-i niveaus - Google Patents

Verwendung eines thienotriazoldiazepins zur erhöhung des apolopoproteins a-i niveaus

Info

Publication number
DE69625696T2
DE69625696T2 DE69625696T DE69625696T DE69625696T2 DE 69625696 T2 DE69625696 T2 DE 69625696T2 DE 69625696 T DE69625696 T DE 69625696T DE 69625696 T DE69625696 T DE 69625696T DE 69625696 T2 DE69625696 T2 DE 69625696T2
Authority
DE
Germany
Prior art keywords
compound
pct
apo
levels
increase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69625696T
Other languages
German (de)
English (en)
Other versions
DE69625696D1 (de
Inventor
Herman Kempen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of DE69625696D1 publication Critical patent/DE69625696D1/de
Publication of DE69625696T2 publication Critical patent/DE69625696T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DE69625696T 1995-09-09 1996-08-30 Verwendung eines thienotriazoldiazepins zur erhöhung des apolopoproteins a-i niveaus Expired - Fee Related DE69625696T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP95114163 1995-09-09
PCT/EP1996/003814 WO1997009048A1 (en) 1995-09-09 1996-08-30 Use of a thienotriazolodiazepine to increase apolipoprotein a-i levels

Publications (2)

Publication Number Publication Date
DE69625696D1 DE69625696D1 (de) 2003-02-13
DE69625696T2 true DE69625696T2 (de) 2003-10-16

Family

ID=8219597

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69625696T Expired - Fee Related DE69625696T2 (de) 1995-09-09 1996-08-30 Verwendung eines thienotriazoldiazepins zur erhöhung des apolopoproteins a-i niveaus

Country Status (14)

Country Link
US (1) US5854238A (enExample)
EP (1) EP0853480B1 (enExample)
JP (1) JPH11512107A (enExample)
KR (1) KR19990044460A (enExample)
CN (1) CN1101680C (enExample)
AT (1) ATE230600T1 (enExample)
AU (1) AU725249B2 (enExample)
BR (1) BR9610390A (enExample)
CA (1) CA2230477A1 (enExample)
DE (1) DE69625696T2 (enExample)
DK (1) DK0853480T3 (enExample)
ES (1) ES2188783T3 (enExample)
TR (1) TR199800406T1 (enExample)
WO (1) WO1997009048A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004925A (en) * 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6518412B1 (en) * 1997-09-29 2003-02-11 Jean-Louis Dasseux Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6253569B1 (en) * 1999-05-07 2001-07-03 James J. Hall Portable storage unit for game animals
WO2003024441A1 (en) 2001-09-14 2003-03-27 Shionogi & Co., Ltd. Novel use of tricyclic compound
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US7144862B2 (en) 2000-08-24 2006-12-05 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US6664230B1 (en) 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7723303B2 (en) 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US7199102B2 (en) * 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7166578B2 (en) 2000-08-24 2007-01-23 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7148197B2 (en) * 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
US8124625B2 (en) 2001-09-14 2012-02-28 Shionogi & Co., Ltd. Method of enhancing the expression of apolipoprotein AI using olefin derivatives
US7429593B2 (en) 2001-09-14 2008-09-30 Shionogi & Co., Ltd. Utilities of amide compounds
US6930085B2 (en) * 2002-04-05 2005-08-16 The Regents Of The University Of California G-type peptides to ameliorate atherosclerosis
RU2414236C2 (ru) 2004-12-06 2011-03-20 Зе Риджентс Оф Зи Юнивесити Оф Кэлифонье Способ улучшения структуры и/или функций артериол
JP2010537638A (ja) 2007-08-28 2010-12-09 ユーエービー リサーチ ファウンデーション 合成アポリポ蛋白質ｅ模倣ポリペプチドおよび使用方法
AU2008296478B9 (en) 2007-08-28 2015-03-19 The Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
US8569288B2 (en) 2008-10-30 2013-10-29 Circomed Llc Thienotriazolodiazepine derivatives active on apo A
CN103119160B (zh) * 2010-05-14 2016-06-01 达那-法伯癌症研究所 用于调节代谢的组合物和方法
HUE031073T2 (en) 2010-05-14 2017-06-28 Dana Farber Cancer Inst Inc Thieno triazolo-diazepine compounds for the treatment of neoplasia
CA2799403C (en) 2010-05-14 2020-01-21 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating leukemia
WO2011143657A1 (en) 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc. Male contraceptive compositions and methods of use
KR20160034379A (ko) 2013-07-25 2016-03-29 다나-파버 캔서 인스티튜트 인크. 전사 인자의 억제제 및 그의 용도
RU2016122654A (ru) 2013-11-08 2017-12-14 Дана-Фарбер Кэнсер Инститьют, Инк. Комбинированная терапия злокачественной опухоли с использованием ингибиторов бромодоменового и экстратерминального (вет) белка
US10793571B2 (en) 2014-01-31 2020-10-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
US10150756B2 (en) 2014-01-31 2018-12-11 Dana-Farber Cancer Institute, Inc. Diaminopyrimidine benzenesulfone derivatives and uses thereof
CA2940472A1 (en) 2014-02-28 2015-09-03 Tensha Therapeutics, Inc. Treatment of conditions associated with hyperinsulinaemia
CA2954475C (en) 2014-07-31 2023-05-16 Uab Research Foundation Apoe mimetic peptides and higher potency to clear plasma cholesterol
EP3177147A4 (en) 2014-08-08 2018-01-24 Dana-Farber Cancer Institute, Inc. Dihydropteridinone derivatives and uses thereof
RU2017104897A (ru) 2014-08-08 2018-09-10 Дана-Фарбер Кэнсер Инститьют, Инк. Производные диазепана и их применения
EA033325B1 (ru) 2014-10-27 2019-09-30 Тэнша Терапеутикс, Инк. Ингибиторы бромодомена
CA2986441A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
KR20180051576A (ko) 2015-09-11 2018-05-16 다나-파버 캔서 인스티튜트 인크. 아세트아미드 티에노트리아졸로디아제핀 및 그의 용도
CN108472300A (zh) 2015-09-11 2018-08-31 达纳-法伯癌症研究所股份有限公司 氰基噻吩并三唑并二氮杂环庚三烯及其用途
PE20181298A1 (es) 2015-11-25 2018-08-07 Dana Farber Cancer Inst Inc Inhibidores de bromodominio bivalentes y usos de los mismos
JP2021527136A (ja) 2018-06-13 2021-10-11 ディブリー・アーゲー 縮合トリアゼピン誘導体の調製及びｂｅｔ阻害剤としてのその使用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4155913A (en) * 1973-02-08 1979-05-22 Hoffmann-La Roche Inc. Thienotriazolodiazepine derivatives
PH12303A (en) * 1973-02-08 1979-01-16 Hoffmann La Roche Thienotriazolodiazepine derivatives
JPS50100096A (enExample) * 1974-01-08 1975-08-08

Also Published As

Publication number Publication date
US5854238A (en) 1998-12-29
KR19990044460A (ko) 1999-06-25
EP0853480B1 (en) 2003-01-08
WO1997009048A1 (en) 1997-03-13
JPH11512107A (ja) 1999-10-19
CA2230477A1 (en) 1997-03-13
DK0853480T3 (da) 2003-05-05
AU6930396A (en) 1997-03-27
BR9610390A (pt) 1999-07-06
MX9801753A (es) 1998-08-30
TR199800406T1 (en) 1998-05-21
AU725249B2 (en) 2000-10-12
ATE230600T1 (de) 2003-01-15
CN1101680C (zh) 2003-02-19
ES2188783T3 (es) 2003-07-01
EP0853480A1 (en) 1998-07-22
CN1195989A (zh) 1998-10-14
DE69625696D1 (de) 2003-02-13

Similar Documents

Publication Publication Date Title
DE69625696T2 (de) Verwendung eines thienotriazoldiazepins zur erhöhung des apolopoproteins a-i niveaus
DE68903215T2 (de) Hypocholesterolaemische und antiatherosklerotische verwendung von bis-(3,5-di-tertiaerbutyl-4-hydroxyphenylthio)methan.
DE69909775T2 (de) Neue fettanaloge zur behandlung von diabetes
DE69431568T2 (de) Inhibierung der migration und proliferation glatter muskeln mit hydroxycarbazolverbindungen
WO1993021912A1 (de) Verwendung einer omega-3-fettsäuren enthaltenden emulsion zur herstellung eines parenteral zu verabreichenden arzneimittels zur behandlung von entzündlichen erkrankungen
DE69636792T2 (de) Verwendung von l-carnitine und acyl derivaten zur senkung des ceramidspiegels
DE69420776T2 (de) Idebenone-haltige Zusammensetzungen zur Behandlung von M. Alzheimer
DE69826674T2 (de) Zusammensetzung, l-carnitin oder alkanoyl l-carnitin und langkettige alkanole enthaltend
DE3781054T2 (de) Die verwendung von d-fenfluramin zur herstellung von arzneimitteln, zur behandlung von depressionen.
DE69129750T2 (de) Neue medizinische anwendung eines gewissen indolderivates und dieses enthaltende pharmazeutische zubereitung
DE2729824A1 (de) Pharmazeutische zusammensetzungen mit organischen montmorillonit-derivaten und ihre herstellung
DE3035494A1 (de) Carnitin enthaltendes arzneimittel zur behandlung von hyperlipidaemie und hyperlipoproteinaemie, sowie verwendung von carnitin zur herstellung eines solchen arzneimittels
DE3311922C2 (de) Verwendung von substituierten 1,4-Benzochinonen bei der Prophylaxe oder Behandlung von Fibrose
DE69501421T2 (de) Hematetrenome Derivat als antiarteriosklerotisches Mittel
EP0765661A2 (en) Use of docosahexaenoic acid for the manufacture of a medicament for the treatment of glumerulonephritis
DE69315162T2 (de) Verwendung von L-Carnitine und Acyl-L-Carnitinen zur Behandlung von Patienten die an AIDS-verwandten Syndromen leiden und von asymptomatischen HIV-seropositiven Patienten
DE3873210T2 (de) Verwendung von benzylpyridin-derivaten zur herstellung eines arzneimittels zur behandlung der demenz.
DE60216118T2 (de) Sesquiterpenoid-derivate mit adipozytendifferenzierungshemmender wirkung
DE69911987T2 (de) Flavonoide aus citrusschalen als kollageninduzierte inhibitoren der blutplättchen-aggregation
DE69115528T2 (de) Neue pharmazeutische Verwendungen von Forskolin-Derivaten
DE602004003173T2 (de) Verwendung von konjugierter Linolsäure zur Behandlung der Erkältung
DE3779991T2 (de) Dioxopiperidin-derivate enthaltende anxiolytische zusammensetzungen.
DE69413544T2 (de) Reduzierte absorption von fettsäuren
EP0094644B1 (de) Verwendung eines Cholecalciferolderivates
DE69302250T2 (de) Verwendung von Isoquinolinon-Derivaten zur Behandlung von Hyperlipoproteinemia

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee